ASCO Annual Meeting 2017

ASCO Annual Meeting 2017

June 2 - 6, 2017
McCormick Place
Chicago, Illinois

Exhibit booth #25105

 

Posters:

DATE, PLACE and TIME:

Monday, June 5,2017, Hall A, 1:15pm - 4:45pm CST

Session: Genitourinary (Prostate) Cancer

Abstract #: 50770

Board #: 144

Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A).

Howard I. Scher, Adam Jendrisak, Nicole A. Schreiber, Brigit McLaughlin, Ryon P Graf, Angel Rodriguez, Martin Fleisher, Jerry Lee, James Kelvin, Yipeng Wang, Mark Andrew Landers, Ryan Dittamore; Memorial Sloan-Kettering Cancer Center, New York, NY; Epic Sciences, Inc., San Diego, CA

 

DATE, PLACE and TIME:

Monday, June 5,2017, Hall A, 1:15pm - 4:45pm CST

Session: Genitourinary (Prostate) Cancer

Abstract #: 5076

Board #: 150

Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx).

Ryan Dittamore, Adam Jendrisak, Nicole A. Schreiber, Brigit McLaughlin, Ryon Graf, Angel Rodriguez, Martin Fleisher, Jerry Lee, James Kelvin, Yipeng Wang, Mark Andrew Landers, Howard I. Scher; Epic Sciences, Inc., San Diego, CA; Memorial Sloan-Kettering Cancer Center, New York, NY

 

DATE, PLACE and TIME:

Monday, June 5,2017, Hall A, 1:15pm - 4:45pm CST

Session: Genitourinary (Prostate) Cancer

Abstract #: 5035

Board #: 109

Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).

Karim Boudadi, Daniel L. Suzman, Brandon Luber, Hao Wang, John Silberstein, Rana Sullivan, Donna Dowling, Rana Harb, Thomas Nirschl, Ryan Dittamore, Michael Anthony Carducci, Mario A. Eisenberger, Michael Haffner, Alan Meeker, James R. Eshleman, Jun Luo, Charles G. Drake, Emmanuel S. Antonarakis; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Johns Hopkins University, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Epic Sciences, Inc., San Diego, CA; The Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, The John Hopkins University School of Medicine, Baltimore, MD; Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

DATE, PLACE and TIME:

Monday, June 5,2017, Hall A, 1:15pm - 4:45pm CST

Session: Genitourinary (Prostate) Cancer

Abstract #: 5034

Board #: 108

Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.

Susan F. Slovin, Karen E. Knudsen, Susan Halabi, Emily Carbone, Celina Fernandez, Yu Chen, Karen A. Autio, Dana E. Rathkopf, Lewis J. Kampel, Michael J. Morris, Gabrielle Arauz, Ryon P Graf, James Kelvin, Ryan Dittamore, Renee De Leeuw, Amanda Sullivan, Kin Tse, Ana M. Molina, Howard I. Scher, William Kevin Kelly; Memorial Sloan-Kettering Cancer Center, New York, NY; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Duke University Medical Center, Durham, NC; Memorial Sloan-Kettering Cancer Center and Weil Cornell Medical College, New York, NY; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Memorial Sloan-Kettering Cancer Center, New York, NY; Epic Sciences, Inc., San Diego, CA; Thomas Jefferson University Kimmel Cancer Center, Philadelphia, PA; Prostate Cancer Clinical Trials Consortium, LLC, New York, NY; Weill Cornell Medical College, New York, NY